Related Experiment Video
Updated: Aug 19, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Raloxifene: another selective estrogen modulator
1Department of Pathobiology and Laboratory Medicine, University of Toronto, Sunnybrook and Women's Health Science Center, Toronto, Ontario M4N 3M5, Canada. eljan@sprint.ca
Abstract:
The role of estrogens as one of the prime stimulators of tumor cell proliferation is well recognized; efforts to interfere with the initiation and promotion of breast and other cancers by endocrine manipulation have a long and successful past. The benzothiophene derivate Raloxifene is a relatively recent newcomer into a heterogeneous family of compounds loosely called antiestrogens, which implies their ability to act as antagonists to estrogen effects via competitive binding to various steroid receptors. This is a reductionist explanation, since their action is colorful and varied; they interact with lipid transduction cascades, covalently bind to DNA and to different proteins and regulate growth factors and the expression of various genes, such as erB2, mdr1 and p53; they complex with E-cadherin/catenin and are thus able to induce apoptosis, actively or indirectly. Raloxifene not only modulates estrogen effects, but has been found to reduce bone demineralization and atherogenesis, without carcinogenic stimulation of the endometrium.
Insights
Raloxifene, an antiestrogen, modulates estrogen effects and offers benefits beyond cancer by reducing bone loss and atherogenesis without stimulating the endometrium.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Estrogens are key stimulators of tumor cell proliferation.
- Endocrine manipulation has a history of success in cancer prevention.
- Antiestrogens, like Raloxifene, are a class of compounds that interfere with estrogen effects.
Purpose of the Study:
- To explore the multifaceted actions of Raloxifene beyond its role as an antiestrogen.
- To investigate Raloxifene's effects on estrogen-sensitive conditions and its broader health implications.
Main Methods:
- Review of existing literature on Raloxifene's mechanisms of action.
- Analysis of Raloxifene's interactions with steroid receptors, cellular pathways, and gene expression.
- Evaluation of clinical and preclinical data on Raloxifene's effects on bone, cardiovascular health, and endometrial tissue.
Main Results:
- Raloxifene acts as an antagonist to estrogen effects via receptor binding.
- It exhibits diverse actions including interaction with lipid cascades, DNA binding, and regulation of growth factors and genes (e.g., erB2, mdr1, p53).
- Raloxifene reduces bone demineralization and atherogenesis and does not stimulate endometrial proliferation.
Conclusions:
- Raloxifene possesses complex pharmacological actions extending beyond simple estrogen antagonism.
- It demonstrates significant therapeutic potential in managing bone loss and cardiovascular disease.
- Raloxifene offers a favorable profile by avoiding the carcinogenic stimulation of the endometrium associated with some other endocrine therapies.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:23Antidepressant Drugs: MAOIs and Other Agents
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...